Presentation, Clinical Course and Patterns of Myocardial Damage Due to Viral Myocarditis

Viral Myocarditis Clinical Trial

Official title:

Presentation, Clinical Course and Patterns of Myocardial Damage Due to Viral Myocarditis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04527835
• Other study ID #: Viral myocarditis
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: March 1, 2021

Study information

• Verified date: August 2020
• Source: Assiut University
• Contact: Shery Asaad, Resident
• Phone: 01270992244
• Email: drshosho31[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Presentation, Clinical Course and Patterns of Myocardial Damage due to Viral Myocarditis

Description:

1. Determine the pattern of myocarditis in hospitalized patients with acute HF within the last 3 months.

2. Determine the pattern of broad spectrum cardiotropic viruses in patients with acute HF within the last 3 months. These viruses like enteroviruses, adenoviruses and parvo B19 virus, HBV, HCV and Covid 19 virus due to its increased prevelance nowadays.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: March 1, 2021
• Est. primary completion date: March 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria: All patients admitted with symptoms , signs and echocardiographic finding suggesting myocarditis within 3 months from start of the symptoms. as acute heart failure, arrhythmias, typical chest pain with ST segment deviation in ECG . dilated cardiomyopathy associated with normal Coronary Angiography, history of upper respiratory tract infection within the last 3 months.

Exclusion Criteria:

1. Patients with significant coronary artery disease.

2. Patient with family history suggesting familial DCMP

3. Critically ill patients.

4. Patients who refuse to do coronary angiography . .

5. Patients with severe valvular heart disease.

6. Pregnant women

7. Patients with raised renal chemistry.

8. Echocardiographic finding showing LVEDD more than 6.5cm

Related Conditions & MeSH terms

• Myocarditis
• Viral Myocarditis

Intervention

Diagnostic Test:
• ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.

Locations

Country	Name	City	State
Egypt	Shery Refaat Asaad	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the pattern of myocarditis in hospitalized patients with acute HF within the last 3 months	All patients admitted with symptoms , signs and echocardiographic finding suggesting myocarditis within 3 months from start of the symptoms. as acute heart failure, arrhythmias, typical chest pain with ST segment deviation in ECG . dilated cardiomyopathy associated with normal Coronary Angiography, history of upper respiratory tract infection within the last 3 months. All will be investigated for determine the pattern of viral myocarditis in those patients	6 months
Secondary	determination of the caustive organism	1. Determine the pattern of broad spectrum cardiotropic viruses in patients with acute HF within the last 3 months. These viruses like enteroviruses, adenoviruses and parvo B19 virus, HBV, HCV and Covid 19 virus due to its increased prevelance nowadays.	6 months